Suven Life Sciences Limited
NSE: SUVEN BSE: SUVEN
Prev Close
192.5
Open Price
193.95
Volume
121,404
Today Low / High
191.11 / 198.5
52 WK Low / High
102.5 / 299.99
Range
188 - 207
Prev Close
192.8
Open Price
192.85
Volume
17,641
Today Low / High
191.5 / 198.4
52 WK Low / High
102.7 / 303
Range
188 - 207
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 197.55 (target range: 188 - 207), reflecting a change of 5.05 (2.62338%). On the BSE, it is listed at 197.45 (target range: 188 - 207), showing a change of 4.65 (2.41183%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Suven Life Sciences Limited Graph
Suven Life Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Suven Life Sciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 197.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range | 
|---|---|---|---|
| Bullish Scenario | 197.45 | 199.42 | 179.48 - 219.37 | 
| 201.40 | 161.12 - 241.68 | ||
| 203.37 | 142.36 - 264.39 | ||
| Bearish Scenario | 197.45 | 195.48 | 175.93 - 215.02 | 
| 193.50 | 154.80 - 232.20 | ||
| 191.53 | 134.07 - 248.98 | 
Overview of Suven Life Sciences Limited
ISIN
INE495B01038
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
155,609
Market Cap
42,016,442,312
Last Dividend
0
Official Website
IPO Date
2003-10-24
DCF Diff
196.97
DCF
-3
Financial Ratios Every Investor Needs
Stock Dividend of SUVEN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date | 
|---|---|---|---|---|---|---|
| 2019-02-14 | February 14, 19 | 1.38194 | 1.5 | 2019-02-15 | 2019-02-25 | 2019-01-29 | 
| 2018-02-06 | February 06, 18 | 1.38194 | 1.5 | 2018-02-07 | 2018-03-01 | 2018-01-19 | 
| 2017-02-08 | February 08, 17 | 0.9213 | 1 | 2017-02-09 | 2017-03-03 | 2017-01-23 | 
| 2016-03-14 | March 14, 16 | 0.9213 | 1 | 2016-03-15 | 2016-03-23 | 2016-03-05 | 
| 2015-07-23 | July 23, 15 | 0.55278 | 0.6 | 2015-07-24 | 2015-09-13 | 2015-05-26 | 
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR | 
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6.66 Cr | 34.29 Cr | -27.63 Cr | -4.1518 | 143.96 Cr | 2.64 Cr | -171.60 Cr | -160.75 Cr | -7.36 | -154.88 Cr | -24.1511 | 
| 2024-03-31 | 11.69 Cr | 0.82 Cr | 10.87 Cr | 0.9295 | 114.43 Cr | 2.71 Cr | -122.58 Cr | -105.08 Cr | -4.82 | -99.28 Cr | -8.9863 | 
| 2023-03-31 | 13.54 Cr | 0.57 Cr | 12.97 Cr | 0.9582 | 115.35 Cr | 2.53 Cr | -131.92 Cr | -118.27 Cr | -7.50 | -111.31 Cr | -8.7352 | 
| 2022-03-31 | 11.84 Cr | 25.58 Cr | -13.73 Cr | -1.1593 | 106.37 Cr | 2.49 Cr | -126.22 Cr | -122.00 Cr | -7.73 | -116.93 Cr | -10.2999 | 
| 2021-03-31 | 13.48 Cr | 0.10 Cr | 13.38 Cr | 0.9924 | 71.03 Cr | 2.29 Cr | -83.87 Cr | -72.15 Cr | -4.57 | -72.19 Cr | -5.3531 | 
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 37.73 Cr | 135.18 Cr | 25.20 Cr | 109.9868 Cr | 0.00 Cr | -37.73 Cr | 0.24 Cr | 59.48 Cr | 0.00 Cr | 0.00 Cr | 0.05 Cr | 23.4860 Cr | 
| 2024-03-31 | 14.93 Cr | 284.90 Cr | 14.86 Cr | 270.0406 Cr | 0.71 Cr | -14.22 Cr | 0.71 Cr | 28.01 Cr | 0.00 Cr | 0.00 Cr | 0.02 Cr | 13.5161 Cr | 
| 2023-03-31 | 37.02 Cr | 388.91 Cr | 13.59 Cr | 375.3193 Cr | 1.61 Cr | -35.41 Cr | 0.01 Cr | 37.02 Cr | 0.00 Cr | 0.00 Cr | 100.00 Cr | 11.1296 Cr | 
| 2022-03-31 | 5.27 Cr | 108.03 Cr | 11.89 Cr | 96.1454 Cr | 3.21 Cr | -2.07 Cr | 0.03 Cr | 40.89 Cr | 4.09 Cr | 0.00 Cr | 0.00 Cr | 8.3147 Cr | 
| 2021-03-31 | 9.35 Cr | 128.42 Cr | 20.41 Cr | 108.0057 Cr | 4.76 Cr | -4.58 Cr | 0.64 Cr | 25.60 Cr | 10.16 Cr | 0.00 Cr | -0.09 Cr | 15.9095 Cr | 
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory | 
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -148.4687 Cr | 149.2715 Cr | -0.7097 Cr | -185.7445 Cr | 0.0460 Cr | 15.0255 Cr | -37.2758 Cr | -160.7450 Cr | -0.7097 Cr | 0.0000 Cr | 0.4710 Cr | 
| 2024-03-31 | -115.4690 Cr | 94.4363 Cr | -1.0540 Cr | -115.4690 Cr | -22.0867 Cr | 14.9324 Cr | 0.0000 Cr | -105.0763 Cr | -0.8956 Cr | 0.0000 Cr | -0.7084 Cr | 
| 2023-03-31 | -103.1482 Cr | -260.6454 Cr | 395.5391 Cr | -106.0430 Cr | 31.7455 Cr | 37.0191 Cr | -2.8948 Cr | -118.2678 Cr | -0.4843 Cr | 0.0000 Cr | 0.0224 Cr | 
| 2022-03-31 | -127.5370 Cr | -22.2292 Cr | 145.6916 Cr | -147.3086 Cr | -4.0746 Cr | 5.2736 Cr | -19.7716 Cr | -121.9951 Cr | -0.8523 Cr | 0.0000 Cr | 0.1191 Cr | 
| 2021-03-31 | -96.0236 Cr | 55.8404 Cr | 34.8556 Cr | -102.3283 Cr | -5.3275 Cr | 9.3482 Cr | -6.3047 Cr | -77.4741 Cr | -0.6924 Cr | 0.0000 Cr | -0.1415 Cr | 
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR | 
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1.87 Cr | 12.50 Cr | 1.87 Cr | 1.0000 | -52.12 Cr | -51.52 Cr | -2.36 | -50.15 Cr | -27.5978 | 
| 2025-03-31 | 1.47 Cr | 9.31 Cr | -7.84 Cr | -5.3459 | -45.17 Cr | -43.94 Cr | -2.01 | -42.60 Cr | -29.9556 | 
| 2024-12-31 | 1.61 Cr | 8.22 Cr | 1.61 Cr | 1.0000 | -40.74 Cr | -39.12 Cr | -1.79 | -37.58 Cr | -24.2975 | 
| 2024-09-30 | 2.57 Cr | 8.65 Cr | 2.57 Cr | 1.0000 | -53.66 Cr | -49.64 Cr | -2.27 | -48.17 Cr | -19.2949 | 
| 2024-06-30 | 1.01 Cr | 8.11 Cr | -7.11 Cr | -7.0638 | -32.02 Cr | -28.04 Cr | -1.29 | -26.53 Cr | -27.8725 | 
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities | 
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 60.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -109.99 Cr | 
| 2025-03-31 | 37.73 Cr | 22.28 Cr | 60.00 Cr | 1.41 Cr | 0.24 Cr | 75.47 Cr | 59.48 Cr | 135.18 Cr | 25.20 Cr | 
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 166.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -192.68 Cr | 
| 2024-09-30 | 92.49 Cr | 73.99 Cr | 166.48 Cr | 1.48 Cr | 0.70 Cr | 186.56 Cr | 25.16 Cr | 211.96 Cr | 19.28 Cr | 
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 239.87 Cr | 0.00 Cr | 0.00 Cr | 239.87 Cr | 0.00 Cr | 0.00 Cr | -270.04 Cr | 
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow | 
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -51.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2025-03-31 | -43.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2024-12-31 | -39.12 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2024-09-30 | -49.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
| 2024-06-30 | -28.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 
Splits History
| Date | Label | Split Ratio | 
|---|---|---|
| 2022-10-17 | October 17, 22 | 217:200 | 
| 2007-03-23 | March 23, 07 | 2:1 | 
| 2004-01-15 | January 15, 04 | 5:1 | 
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume | 
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,690.70 | ₹4,056,549,508,373.00 | ₹1,560,907.00 | 
| Divi's Laboratories Limited | DIVISLAB | ₹6,738.00 | ₹1,788,732,898,056.00 | ₹507,645.00 | 
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,560.10 | ₹1,204,898,044,500.00 | ₹354,021.00 | 
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,197.60 | ₹996,839,216,220.00 | ₹4,250,056.00 | 
| Mankind Pharma Limited | MANKIND | ₹2,384.00 | ₹984,016,240,160.00 | ₹593,366.00 | 
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.45 | ₹980,520,395,716.00 | ₹458,971.00 | 
| Lupin Limited | LUPIN | ₹1,963.50 | ₹896,844,333,000.00 | ₹1,017,447.00 | 
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,138.90 | ₹661,474,968,435.00 | ₹3,556,831.00 | 
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹178,327.00 | 
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,891.20 | ₹533,698,169,981.00 | ₹398,054.00 | 
| Laurus Labs Limited | LAURUSLABS | ₹953.65 | ₹514,804,014,931.00 | ₹1,545,364.00 | 
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 | 
| Ipca Laboratories Limited | IPCALAB | ₹1,271.20 | ₹322,508,801,922.00 | ₹106,442.00 | 
| Ajanta Pharma Limited | AJANTPHARM | ₹2,465.30 | ₹308,003,793,847.00 | ₹102,941.00 | 
| Cohance Lifesciences Limited | COHANCE | ₹753.40 | ₹288,226,083,276.00 | ₹1,868,840.00 | 
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,682.30 | ₹263,441,852,870.00 | ₹161,890.00 | 
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 | 
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,318.90 | ₹250,017,076,708.00 | ₹201,166.00 | 
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,555.00 | ₹238,875,000,000.00 | ₹20,033.00 | 
| Eris Lifesciences Limited | ERIS | ₹1,591.70 | ₹216,811,113,902.00 | ₹40,393.00 | 
| Neuland Laboratories Limited | NEULANDLAB | ₹16,473.00 | ₹211,346,761,497.00 | ₹44,604.00 | 
| Wockhardt Limited | WOCKPHARMA | ₹1,281.50 | ₹208,224,272,482.00 | ₹289,135.00 | 
| Alembic Pharmaceuticals Limited | APLLTD | ₹897.40 | ₹176,395,747,478.00 | ₹69,233.00 | 
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,101.00 | ₹174,564,413,184.00 | ₹543,954.00 | 
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,032.80 | ₹154,516,575,629.00 | ₹43,860.00 | 
| NATCO Pharma Limited | NATCOPHARM | ₹819.90 | ₹146,852,182,413.00 | ₹412,467.00 | 
| Granules India Limited | GRANULES | ₹565.60 | ₹137,253,425,770.00 | ₹384,397.00 | 
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 | 
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.45 | ₹110,959,145,199.00 | ₹27,710.00 | 
| Procter & Gamble Health Limited | PGHL | ₹6,152.00 | ₹102,119,398,064.00 | ₹17,413.00 | 
| Strides Pharma Science Limited | STAR | ₹934.70 | ₹86,153,835,776.00 | ₹9,219,602.00 | 
| Aarti Pharmalabs Limited | AARTIPHARM | ₹851.95 | ₹77,214,757,940.00 | ₹105,286.00 | 
| FDC Limited | FDC | ₹460.65 | ₹74,998,465,195.00 | ₹252,540.00 | 
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹460.75 | ₹70,541,773,224.00 | ₹53,334.00 | 
| Shilpa Medicare Limited | SHILPAMED | ₹352.85 | ₹69,011,043,776.00 | ₹149,611.00 | 
| Sequent Scientific Limited | SEQUENT | ₹214.61 | ₹53,633,796,524.00 | ₹1,034,635.00 | 
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹465.10 | ₹50,679,744,752.00 | ₹51,856.00 | 
| Innova Captab Limited | INNOVACAP | ₹831.10 | ₹47,559,638,492.00 | ₹13,222.00 | 
| Aarti Drugs Limited | AARTIDRUGS | ₹491.10 | ₹44,822,697,000.00 | ₹54,690.00 | 
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.19 | ₹43,872,073,482.00 | ₹196,488.00 | 
| Suven Life Sciences Limited | SUVEN | ₹197.55 | ₹43,073,939,692.00 | ₹121,404.00 | 
| RPG Life Sciences Limited | RPGLIFE | ₹2,403.90 | ₹39,758,138,159.00 | ₹6,281.00 | 
| Orchid Pharma Limited | ORCHPHARMA | ₹726.30 | ₹36,837,285,962.00 | ₹86,074.00 | 
| Unichem Laboratories Limited | UNICHEMLAB | ₹470.95 | ₹33,157,587,963.00 | ₹3,282.00 | 
| Gufic Biosciences Limited | GUFICBIO | ₹325.40 | ₹32,631,927,452.00 | ₹54,623.00 | 
Key Executives
Gender: female
Year Born: 1979
Gender: male
Year Born: 1949
Gender: male
Year Born:
Gender: female
Year Born: 1954
Gender: male
Year Born:
FAQs about Suven Life Sciences Limited
The CEO is Venkateswarlu Jasti M.Pharm..
The current price is ₹192.70.
The range is ₹102.5-299.99.
The market capitalization is ₹4,201.64 crores.
The P/E ratio is -22.83.
The company operates in the Healthcare sector.
Overview of Suven Life Sciences Limited (ISIN: INE495B01038) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,201.64 crores and an average daily volume of 155,609 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.
